|Bid||35.65 x 800|
|Ask||35.87 x 800|
|Day's Range||35.51 - 36.06|
|52 Week Range||21.79 - 38.99|
|Beta (3Y Monthly)||1.51|
|PE Ratio (TTM)||39.19|
|Earnings Date||Oct 24, 2017 - Oct 30, 2017|
|Forward Dividend & Yield||0.34 (0.96%)|
|1y Target Est||33.71|
Chairman and CEO of Lemaitre Vascular Inc (30-Year Financial, Insider Trades) George W Lemaitre (insider trades) sold 38,695 shares of LMAT on 09/13/2019 at an average price of $34.86 a share. Continue reading...
George LeMaitre became the CEO of LeMaitre Vascular, Inc. (NASDAQ:LMAT) in 1992. This report will, first, examine the...
BURLINGTON, Mass., Aug. 26, 2019 -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will be presenting at the Wells Fargo Healthcare Conference, Baird Global.
LeMaitre Vascular, Inc. (NASDAQ:LMAT) is about to trade ex-dividend in the next 2 days. You can purchase shares before...
LeMaitre Vascular, Inc. (NASDAQ:LMAT), which is in the medical equipment business, and is based in United States, saw...
BURLINGTON, Mass., July 30, 2019 -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that JJ Pellegrino, Chief Financial Officer, will present at the Canaccord Genuity.
LeMaitre Vascular, Inc. (LMAT) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Chairman and CEO of Lemaitre Vascular Inc (30-Year Financial, Insider Trades) George W Lemaitre (insider trades) sold 66,037 shares of LMAT on 07/25/2019 at an average price of $34.45 a share. Continue reading...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 24) Acasti Pharma Inc (NASDAQ: ACST ) Cardiovascular Systems ...
LeMaitre (LMAT) delivered earnings and revenue surprises of 9.52% and 1.89%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
BURLINGTON, Mass., July 24, 2019 -- LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q2 2019 results, provided.
LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...
BURLINGTON, Mass., July 11, 2019 -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its second quarter 2019 financial results on Wednesday, July 24,.